These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 33250273)

  • 1. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
    Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
    Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.
    Moscarelli J; Zahavi D; Maynard R; Weiner LM
    Transplant Cell Ther; 2022 Oct; 28(10):650-656. PubMed ID: 35788086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.
    Bollino D; Webb TJ
    Transl Res; 2017 Sep; 187():32-43. PubMed ID: 28651074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges.
    Wu J
    BioDrugs; 2024 Jul; 38(4):499-509. PubMed ID: 38700835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.
    Tsiverioti CA; Gottschlich A; Trefny M; Theurich S; Anders HJ; Kroiss M; Kobold S
    Biol Chem; 2024 Jul; 405(7-8):485-515. PubMed ID: 38766710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.
    Shin S; Lee P; Han J; Kim SN; Lim J; Park DH; Paik T; Min J; Park CG; Park W
    Tissue Eng Regen Med; 2023 Jun; 20(3):371-387. PubMed ID: 36867402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.
    Kilgour MK; Bastin DJ; Lee SH; Ardolino M; McComb S; Visram A
    Front Immunol; 2023; 14():1166038. PubMed ID: 37205115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and new technologies in adoptive cell therapy.
    Zhang P; Zhang G; Wan X
    J Hematol Oncol; 2023 Aug; 16(1):97. PubMed ID: 37596653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.